Skip to main content
Top

06-07-2024 | Insulins | Review

Diabetes current and future translatable therapies

Authors: Fabio Antonio Gonzalez-Sanchez, Triana Mayra Sanchez-Huerta, Alexandra Huerta-Gonzalez, Maricruz Sepulveda-Villegas, Julio Altamirano, Juan Pablo Aguilar-Aleman, Rebeca Garcia-Varela

Published in: Endocrine

Login to get access

Abstract

Diabetes is one of the major diseases and concerns of public health systems that affects over 200 million patients worldwide. It is estimated that 90% of these patients suffer from diabetes type 2, while 10% present diabetes type 1. This type of diabetes and certain types of diabetes type 2, are characterized by dysregulation of blood glycemic levels due to the total or partial depletion of insulin-secreting pancreatic β-cells. Different approaches have been proposed for long-term treatment of insulin-dependent patients; amongst them, cell-based approaches have been the subject of basic and clinical research since they allow blood glucose level sensing and in situ insulin secretion. The current gold standard for insulin-dependent patients is on-demand exogenous insulin application; cell-based therapies aim to remove this burden from the patient and caregivers. In recent years, protocols to isolate and implant pancreatic islets from diseased donors have been developed and tested in clinical trials. Nevertheless, the shortage of donors, along with the need of immunosuppressive companion therapies, have pushed researchers to focus their attention and efforts to overcome these disadvantages and develop alternative strategies. This review discusses current tested clinical approaches and future potential alternatives for diabetes type 1, and some diabetes type 2, insulin-dependent patients. Additionally, advantages and disadvantages of these discussed methods
Literature
3.
go back to reference L. Poretsky. Principles of diabetes mellitus. Principles of Diabetes Mellitus. (Springer Science+Business Media, New Orleans), 2010) 203–220CrossRef L. Poretsky. Principles of diabetes mellitus. Principles of Diabetes Mellitus. (Springer Science+Business Media, New Orleans), 2010) 203–220CrossRef
8.
go back to reference Ogle G.D., Wang F., Gregory G.A., Maniam J. Type 1 Diabetes estimates in children and adults. Int Diabetes Fed Reports 1–15 (2022). Ogle G.D., Wang F., Gregory G.A., Maniam J. Type 1 Diabetes estimates in children and adults. Int Diabetes Fed Reports 1–15 (2022).
20.
go back to reference Tesauro M., Mazzotta F.A. Pathophysiology of diabetes. Elsevier Inc. (2019). Tesauro M., Mazzotta F.A. Pathophysiology of diabetes. Elsevier Inc. (2019).
25.
go back to reference Gómez-Díaz R.A. Pathophysiology of Type 1 Diabetes. In: Rodriguez-Saldana J. (ed) The Diabetes Textbook: Clinical Principles, Patient Management and Public Health Issues. Springer International Publishing, Cham, pp 89–99 (2019) Gómez-Díaz R.A. Pathophysiology of Type 1 Diabetes. In: Rodriguez-Saldana J. (ed) The Diabetes Textbook: Clinical Principles, Patient Management and Public Health Issues. Springer International Publishing, Cham, pp 89–99 (2019)
33.
go back to reference R. Mallone, D.L. Eizirik, Presumption of innocence in type 1 diabetes: Why are beta cells such vulnerable autoimmune targets? Diabetologia 63, 1999–2006 (2020). In PressCrossRefPubMed R. Mallone, D.L. Eizirik, Presumption of innocence in type 1 diabetes: Why are beta cells such vulnerable autoimmune targets? Diabetologia 63, 1999–2006 (2020). In PressCrossRefPubMed
35.
go back to reference Adi S., Gerard-Gonzalez A. Chapter 1 - Type 1 Diabetes Mellitus: An Overview. In: Bagchi D., Nair S. (eds) Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome (Second Edition), Second Edi. Academic Press, pp 3–13 (2018). Adi S., Gerard-Gonzalez A. Chapter 1 - Type 1 Diabetes Mellitus: An Overview. In: Bagchi D., Nair S. (eds) Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome (Second Edition), Second Edi. Academic Press, pp 3–13 (2018).
41.
go back to reference J. Blahova, M. Martiniakova, M. Babikova et al. Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus. Pharmaceuticals 14, 806 (2021)CrossRefPubMedPubMedCentral J. Blahova, M. Martiniakova, M. Babikova et al. Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus. Pharmaceuticals 14, 806 (2021)CrossRefPubMedPubMedCentral
55.
go back to reference Emamaullee J.A., Pepper A., Shapiro A.M.J. Chapter 56 - Islet Cell Transplantation. In: Atala A., Lanza R., Mikos A.G., Nerem R. (eds) Principles of Regenerative Medicine (Third Edition), Third Edit. Academic Press, Boston, pp 987–1007 (2019) Emamaullee J.A., Pepper A., Shapiro A.M.J. Chapter 56 - Islet Cell Transplantation. In: Atala A., Lanza R., Mikos A.G., Nerem R. (eds) Principles of Regenerative Medicine (Third Edition), Third Edit. Academic Press, Boston, pp 987–1007 (2019)
56.
go back to reference R.D. Molano, A. Pileggi, T. Berney et al. Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody1. Transplantation 75, 1812–1819 (2003)CrossRefPubMed R.D. Molano, A. Pileggi, T. Berney et al. Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody1. Transplantation 75, 1812–1819 (2003)CrossRefPubMed
64.
74.
go back to reference G.E. Sonnenberg, M. Berger, Human Insulin: Much ado about one amino acid? Diabetologia 25, 457–459 (1983)CrossRefPubMed G.E. Sonnenberg, M. Berger, Human Insulin: Much ado about one amino acid? Diabetologia 25, 457–459 (1983)CrossRefPubMed
83.
go back to reference T. Mochida, H. Ueno, N. Tsubooka-Yamazoe et al. Insulin-deficient diabetic condition upregulates the insulin-secreting capacity of human induced pluripotent stem cell–derived pancreatic endocrine progenitor cells after implantation in mice. Diabetes 69, 634–646 (2020). https://doi.org/10.2337/db19-0728CrossRefPubMed T. Mochida, H. Ueno, N. Tsubooka-Yamazoe et al. Insulin-deficient diabetic condition upregulates the insulin-secreting capacity of human induced pluripotent stem cell–derived pancreatic endocrine progenitor cells after implantation in mice. Diabetes 69, 634–646 (2020). https://​doi.​org/​10.​2337/​db19-0728CrossRefPubMed
103.
go back to reference B. Liang, J. Chen, T. Li et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Med. (Baltim.) 99, e21429 (2020)CrossRef B. Liang, J. Chen, T. Li et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Med. (Baltim.) 99, e21429 (2020)CrossRef
109.
go back to reference L. Xu, C. Xu, S. Zhou et al. PAX4 promotes PDX1-induced differentiation of mesenchymal stem cells into insulin-secreting cells. Am. J. Transl. Res 9, 874–886 (2017).PubMedPubMedCentral L. Xu, C. Xu, S. Zhou et al. PAX4 promotes PDX1-induced differentiation of mesenchymal stem cells into insulin-secreting cells. Am. J. Transl. Res 9, 874–886 (2017).PubMedPubMedCentral
Metadata
Title
Diabetes current and future translatable therapies
Authors
Fabio Antonio Gonzalez-Sanchez
Triana Mayra Sanchez-Huerta
Alexandra Huerta-Gonzalez
Maricruz Sepulveda-Villegas
Julio Altamirano
Juan Pablo Aguilar-Aleman
Rebeca Garcia-Varela
Publication date
06-07-2024
Publisher
Springer US
Keywords
Insulins
Insulins
Published in
Endocrine
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-024-03944-8
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare